Japan, July 9 -- REGENERON PHARMACEUTICALS INC has got intellectual property rights for 'BISPECIFIC ANTI-PSMAxANTI-CD28 ANTIBODIES AND USES THEREOF.' Other related details are as follows:

Application Number: JP,2025-075081

Category (FI): C07K16/46,A61K31/407,A61K31/475,A61K31/513,A61K31/52,A61K31/519,A61K31/365,A61K31/196,A61K31/255,A61K31/573,A61K31/7048,A61K31/282,A61K31/138,A61P13/08,A61P35/00,A61P43/00,121,A61K45/00,A61K39/395@N,A61K39/395@D,C07K16/30,C12P21/08,C12N5/10,C12N1/21,C12N1/19,C12N1/15,C12N15/63@Z,C12N15/13,C07K16/28

Stage: Grant (IP right granted following substantive examination.)

Filing Date: April 30, 2025

Publication Date: Aug. 20, 2025

The original document can be viewed at: https://www.j-platpat.inpit.go.jp/p0100...